Clinical TrialOct 23, 2026, 05:07 PM
Cumberland Pharmaceuticals: Phase 2a Trial Results for Ifetroban in Systemic Sclerosis
AI Summary
Cumberland Pharmaceuticals Inc. (CPIX) has announced top-line results from its Phase 2a ASSIST-SSc trial, which evaluated the use of oral ifetroban in patients diagnosed with systemic sclerosis. The trial's outcomes indicate that ifetroban is safe and well-tolerated within this specific patient group suffering from the rare disease. Further details are available in the press release furnished as Exhibit 99.1.
Key Highlights
- Cumberland Pharmaceuticals Inc. announced top-line results from its Phase 2a ASSIST-SSc trial.
- The trial evaluated oral ifetroban for patients with systemic sclerosis.
- Results support the safety and tolerability of ifetroban in this rare disease population.
Price Impact
More from CPIX